FACTORS OF ACCESS TO THE MARKET OF INNOVATIVE SPECIALTIES IN ALGERIA: THE CASE OF HOSPITAL DRUGS

被引：0
|
作者：
Djafri, R. [1 ]
Djemai, S. [1 ]
Aissaoui, A. [2 ]
Laichour, A. [2 ]
Boudis, A. [1 ]
机构：
[1] Fac Pharm, Algiers, Algeria
[2] Sanofi, Algiers, Algeria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR145
引用
收藏
页码：S258 / S259
页数：2
相关论文
共 50 条
  • [41] THE DETERMINANTS OF INNOVATIVE DRUGS PRICES: THE CASE OF ONCOLOGY DRUGS, COMPARATIVE ANALYSIS
    Aissaoui, A.
    Levy, P.
    VALUE IN HEALTH, 2016, 19 (07) : A350 - A350
  • [42] Accelerating access to innovative oncology drugs: Insights from France's early access reform
    Martin, T.
    Bayle, A.
    Marabelle, A.
    Massard, C. P.
    Borget, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S943 - S943
  • [43] Strategic Analysis of an innovative Business Model in the Wireless Internet Access Market
    Yun, Qing
    Vidales, Pablo
    Solarski, Marcin
    Hoeft, Uwe
    IITSI 2009: SECOND INTERNATIONAL SYMPOSIUM ON INTELLIGENT INFORMATION TECHNOLOGY AND SECURITY INFORMATICS, 2009, : 68 - +
  • [44] Skip pattern approach toward the early access of innovative anticancer drugs
    Apolone, G.
    Ardizzoni, A.
    Biondi, A.
    Bortolami, A.
    Cardone, C.
    Ciniselli, C. M.
    Conte, P.
    Crippa, C.
    de Braud, F.
    Duca, M.
    Gori, S.
    Gritti, G.
    Inno, A.
    Luksch, R.
    Lussana, F.
    Maio, M.
    Pasello, G.
    Perrone, F.
    Rambaldi, A.
    Rossi, G.
    Signorelli, D.
    Soverini, G.
    Valente, M.
    Verderio, P.
    Buzzetti, G.
    ESMO OPEN, 2021, 6 (04)
  • [45] Market-access agreements for anti-cancer drugs
    van de Vooren, Katelijne
    Curto, Alessandro
    Freemantle, Nick
    Garattini, Livio
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2015, 108 (05) : 166 - 170
  • [46] QUALITATIVE ASSESSMENT OF SOCIETAL PREFERENCES FOR MARKET ACCESS OF CANCER DRUGS
    Pauwels, K.
    Huys, I
    Casteels, M.
    Simoens, S.
    VALUE IN HEALTH, 2015, 18 (07) : A486 - A486
  • [47] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [48] THE IMPACT ON ACCESS TO INNOVATIVE DRUGS OF THE FIRST MANAGED ENTRY AGREEMENTS IN ROMANIA
    Chiriac, N. D.
    Radu, P. C.
    Pravat, M. A.
    VALUE IN HEALTH, 2016, 19 (07) : A503 - A503
  • [49] SCAN: AN INTEGRATED SYSTEM FOR MARKET ACCESS OF NEW DRUGS IN ITALY
    Lanati, E. P.
    Lidonnici, D.
    D'Ausilio, A.
    Iorio, A.
    Jommi, C.
    VALUE IN HEALTH, 2011, 14 (07) : A425 - A425
  • [50] Expanded access and commercial packaging for niche-market drugs
    Jones, Karl
    Stark, Matthew
    Manufacturing Chemist, 2020, 91 (01): : 26 - 28
12345